Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 15Completed 9Unknown 6Not yet recruiting 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 2Gynecologic 2Other solid neoplasm 1Genitourinary 1

Conditions

Advanced Solid Tumor 1

Interventions

pembrolizumab 26Cisplatin 15Pemetrexed 14Paclitaxel 14Carboplatin 14Nivolumab 9Cyclophosphamide 9Docetaxel 8Injections 7atezolizumab 6Melphalan 6olaparib 5Gemcitabine 5Filgrastim 5tislelizumab 4durvalumab 4aldesleukin 4Leucovorin 4Irinotecan 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bevacizumab 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3defactinib 3adavosertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × toripalimab × Other solid neoplasm × Clear all
NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Ascentage Pharma Group Inc.

Phase 1/2 Terminated
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡